Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
Tevogen Bio Holdings (Nasdaq: TVGN) reported significant growth in institutional ownership during Q2 2025. The company saw a 24% increase in institutional ownership compared to Q1 2025, following a 60% increase in the previous quarter.
Notable developments include Morgan Stanley and BlackRock increasing their combined holdings by 80%. The number of institutional holders grew from 51 to 55, with 72% of holders either increasing or maintaining their positions. The company attributes this growth to its scientific and operational progress, including positive clinical data and advancement toward internal GMP cell manufacturing capabilities.
Tevogen Bio Holdings (Nasdaq: TVGN) ha registrato una crescita significativa della partecipazione istituzionale nel secondo trimestre 2025. La società ha rilevato un aumento del 24% della proprietà istituzionale rispetto al primo trimestre 2025, dopo un incremento del 60% nel trimestre precedente.
Tra gli eventi di rilievo, Morgan Stanley e BlackRock hanno incrementato le loro partecipazioni congiunte del 80%. Il numero di detentori istituzionali è salito da 51 a 55, con il 72% degli investitori che ha aumentato o mantenuto le proprie posizioni. La società attribuisce questa crescita ai progressi scientifici e operativi, inclusi dati clinici positivi e l'avanzamento verso capacità interne di produzione cellulare GMP.
Tevogen Bio Holdings (Nasdaq: TVGN) informó un crecimiento significativo en la propiedad institucional durante el segundo trimestre de 2025. La compañía registró un incremento del 24% en la propiedad institucional respecto al primer trimestre de 2025, tras un aumento del 60% en el trimestre anterior.
Entre los hechos destacados, Morgan Stanley y BlackRock aumentaron sus participaciones combinadas en un 80%. El número de titulares institucionales creció de 51 a 55, y el 72% de los inversores aumentó o mantuvo sus posiciones. La empresa atribuye este crecimiento a sus avances científicos y operativos, incluidos datos clínicos positivos y el progreso hacia capacidades internas de fabricación celular GMP.
Tevogen Bio Holdings (Nasdaq: TVGN)는 2025년 2분기 동안 기관 보유 비중이 크게 증가했다고 보고했습니다. 회사는 2025년 1분기 대비 기관 보유가 24% 증가했으며, 이전 분기에는 60% 증가했다고 밝혔습니다.
주요 내용으로는 Morgan Stanley와 BlackRock이 합산 보유량을 80% 늘린 것이 포함됩니다. 기관 보유자 수는 51명에서 55명으로 증가했으며, 보유자의 72%가 포지션을 늘리거나 유지했습니다. 회사는 이러한 성장을 긍정적 임상 데이터 및 내부 GMP 세포 제조 역량 향상을 포함한 과학적·운영적 진전 덕분으로 설명하고 있습니다.
Tevogen Bio Holdings (Nasdaq: TVGN) a annoncé une croissance significative de la détention institutionnelle au deuxième trimestre 2025. La société a enregistré une hausse de 24% de la participation institutionnelle par rapport au premier trimestre 2025, après une augmentation de 60% au trimestre précédent.
Parmi les faits marquants, Morgan Stanley et BlackRock ont augmenté leurs avoirs combinés de 80%. Le nombre de détenteurs institutionnels est passé de 51 à 55, et 72% des détenteurs ont augmenté ou maintenu leurs positions. La société attribue cette croissance à ses progrès scientifiques et opérationnels, notamment des données cliniques positives et l'avancement vers des capacités internes de fabrication cellulaire conformes aux normes GMP.
Tevogen Bio Holdings (Nasdaq: TVGN) meldete im zweiten Quartal 2025 ein deutliches Wachstum der institutionellen Eigentümerstruktur. Das Unternehmen verzeichnete im Vergleich zum ersten Quartal 2025 einen Anstieg der institutionellen Beteiligung um 24%, nach einem 60%igen Anstieg im vorangegangenen Quartal.
Zu den bemerkenswerten Entwicklungen gehört, dass Morgan Stanley und BlackRock ihre kombinierten Bestände um 80% erhöhten. Die Zahl der institutionellen Inhaber stieg von 51 auf 55, wobei 72% der Inhaber ihre Positionen erhöhten oder beibehielten. Das Unternehmen führt dieses Wachstum auf seine wissenschaftlichen und operativen Fortschritte zurück, darunter positive klinische Daten und Fortschritte beim Aufbau interner GMP-konformer Zellproduktionskapazitäten.
- Institutional ownership increased by 24% in Q2 2025
- Morgan Stanley and BlackRock increased combined holdings by 80%
- Number of institutional holders grew from 51 to 55
- 72% of institutional holders increased or maintained their positions
- Company is advancing toward internal GMP cell manufacturing capabilities
- Company needs to raise additional capital to execute business plan
- Faces risks in maintaining effective internal controls
- Limited operating history presents operational risks
- Potential challenges in keeping pace with rapid technological developments
Insights
Tevogen's 24% Q2 increase in institutional ownership signals growing confidence from sophisticated investors despite early-stage status.
The 24% increase in institutional ownership during Q2 2025 (following a 60% increase in Q1) represents a significant vote of confidence from sophisticated market participants. Particularly noteworthy is the 80% increase in holdings from financial powerhouses Morgan Stanley and BlackRock, which typically employ rigorous due diligence processes before increasing positions. The expansion from 51 to 55 institutional holders with 72% either maintaining or increasing their stakes demonstrates broadening institutional interest.
This pattern of institutional accumulation often precedes broader market recognition. Institutional investors typically have longer investment horizons and higher risk tolerance for early-stage biopharmaceutical companies, suggesting they're valuing Tevogen's pipeline and technological approach despite the inherent risks of the sector.
While specific operational details remain limited in this release, the mention of "positive clinical data" and progress toward "internal GMP cell manufacturing capabilities" provides context for the institutional interest. The development of in-house manufacturing represents a strategic move to control production costs and quality, potentially improving margins if products reach commercialization.
However, the forward-looking statements section flags significant challenges ahead, including capital requirements, regulatory hurdles, and commercialization risks. The company's "limited operating history" mentioned in the risk factors suggests Tevogen remains in early development stages, making this level of institutional interest particularly noteworthy for a company at this phase.
WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company’s outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC).
As reported on June 30, 2025, second quarter institutional ownership of Tevogen common stock increased
“The continued increase in ownership by institutional managers is a positive sign and may reflect how Tevogen’s scientific and operational progress is resonating with long-term investors,” said Tapan Shah, Tevogen’s Head of Investor Relations. “We believe the Company’s milestones, from publishing positive clinical data to advancing toward internal GMP cell manufacturing capabilities, could further strengthen institutional confidence in our ability to execute on our mission.”
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What was Tevogen's (TVGN) institutional ownership growth in Q2 2025?
How many institutional holders does Tevogen (TVGN) have as of Q2 2025?
Which major institutions increased their holdings in Tevogen (TVGN)?
What operational developments is Tevogen (TVGN) pursuing?
What are the main risks facing Tevogen (TVGN)?
